�Health Discovery Corporation ("HDC") (OTCBB: HDVY) announced that HDC's unexampled gene-based molecular diagnostic test for prostate gland cancer has now successfully completed it's Phase III double-blind clinical trial and is now ready for commercialization to be used by physicians on their patients at risk of having prostate gland cancer. The new prostate cancer try out will be performed at Clarient's Clinical Laboratory in Aliso Viejo, CA. HDC will receive 30% royalty on each test performed.
Results from Phase I, Phase II and Phase III double-blinded clinical validation studies now completed with prostate tissues obtained from multiple sites, including those tested in collaboration with MD Anderson Cancer Center, demonstrated a very high success rate for identifying the front of Grade 3 or higher prostate cancer cells (clinically significant cancer), as well as, normal and BPH (benign prostatic hyperplasia) cells. To date, 322 prostate tissues have been tested. The combined results of the recently accomplished double-blinded clinical validation studies demonstrated that the
